Mednet Logo
HomeEndocrinology
Endocrinology

Endocrinology

Physician discussions on diabetes management, thyroid disorders, hormonal imbalances, and metabolic conditions.

Recent Discussions

How do you approach treatment of osteoporosis in patients with CKD who develop a fragility fracture while on denosumab?

7
1 Answers

Mednet Member
Mednet Member
Rheumatology · UC Davis

The only option left at this point is a PTH compound. Please it or not, it still works every time in subjects with a secondary elevation of PTH. I would try either Forteo or Tymlos for a few months and see if the patient can tolerate it and if the calcium numbers remain stable. I am not sure about r...

How do you approach prophylaxis against glucocorticoid-induced osteoporosis in patients with end-stage renal disease on dialysis?

4
1 Answers

Mednet Member
Mednet Member
Rheumatology · UC Davis

Treating patients with end-stage renal disease on glucocorticoids to prevent bone loss is a challenge. A patient with end-stage renal disease cannot be treated with bisphosphonates. However, denosumab the RANKL antibody has no restrictions regarding renal disease. So my suggestion is to treat a pati...

How do you diagnose and treat patients who develop uveitis while on bisphosphonate therapy for osteoporosis?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Legacy Devers Eye Institute

Ocular inflammation, usually anterior uveitis, can occur as a consequence of bisphosphonate therapy. Virtually always, the bisphosphonate is one that is given intravenously and the ocular inflammation begins a day or two after the treatment. Furthermore, the inflammation is generally self-limited; i...

How would you approach osteoporosis management in a patient who fractures while on denosumab therapy?

1 Answers

Mednet Member
Mednet Member
Rheumatology · University Rheumatologists

This is a scenario that we run into at times and is very difficult with data suggesting a decline in BMD after discontinuation of denosumab as well as data from DATA-Switch trial from 2015 revealed that switching from denosumab to teriparatide resulted in progressive or transient bone loss. I would ...

How do you manage anaplastic thyroid cancer that is progressing through radiation therapy?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Texas MD Anderson Cancer Center

The algorithms for ATC, a rare disease, have gotten relatively complex including the incorporation and timing of XRT. It is unclear from the question what the presentation scenario is, i.e., localized disease or metastatic, and the mutational status, as ideally at a minimum BRAF status is known. Now...

Would you consider use of an oral bisphosphonate (such as alendronate liquid) in a patient with eosinophilic esophagitis?

1 Answers

Mednet Member
Mednet Member
Rheumatology · NYU Langone

My general approach to patients with any form of esophagitis for whom bisphosphonate therapy is indicated is to treat with zoledronate. I am not aware of any data that has reviewed the use of a liquid form of a bisphosphonate for patients with esophageal disorders including eosinophilic esophagitis,...

When do you include the neck in the RT field for resected thyroid cancer?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Karmanos Cancer Institute - McLaren Proton Therapy Center

I will use external beam RT to the neck for medullary thyroid cancer, anaplastic thyroid cancer, or local-regional recurrence of papillary or follicular that is no longer iodine-avid, and thus cannot be treated by I-131.

In a patient with inflammatory orbital disease without a discrete mass to biopsy and recent bisphosphonate use, how much additional workup would you do if basic labs, urine studies, ANCA serologies, thyroid studies, chest imaging (to r/out sarcoid) are normal, before concluding that the process is likely secondary to bisphosphonate use?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Legacy Devers Eye Institute

Bisphosphonates are a known but rare cause of orbital inflammation. An intravenously administered bisphosphonate is far more likely to cause this compared to an oral drug. There is usually a close temporal association between taking the medication and developing the inflammation. The diagnosis is on...

For someone with asymmetric Graves ophthalmopathy, do you still treat both eyes, or target the single affected orbit?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Physician Health Partners

Single site.

When tapering moderate to high doses of long term steroids do you routinely monitor for adrenal insufficiency?

4
2 Answers

Mednet Member
Mednet Member
Rheumatology · Mobile Medical Care Inc

This is always a good question on which to reflect. In general, moderate dosing of steroids (> or = 20 mg prednisone equivalents) for 5 days or less do not need a taper and pose low risk of adrenal suppression, and by extension chronic adrenal insufficiency. Up to date suggests that up to 3 weeks is...